{"nctId":"NCT05425745","briefTitle":"Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.","startDateStruct":{"date":"2022-07-25","type":"ACTUAL"},"conditions":["Dyslipidemias","High Cholesterol","Hypercholesterolemia","Familial Hypercholesterolemia","Lipid Metabolism Disorder","Metabolic Disease","Lipid Metabolism, Inborn Errors","Genetic Disease, Inborn","Hyperlipoproteinemias"],"count":354,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Obicetrapib 10 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Obicetrapib"]}],"interventions":[{"name":"Obicetrapib","otherNames":["CETP-inhibitor"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have a history of heterozygous familial hypercholesterolemia (HeFH) by 1) Genotyping (not a screening assessment), WHO Criteria/Dutch Lipid Clinical Network Criteria with a score of \\> 8 points; and/or Simon Broome Register Diagnostic Criteria for definite or possible Familial Hypercholesterolemia (FH)\n* Maximally tolerated lipid Modifying therapy for at least 8 weeks prior to screening such as: ATV (40 or 80), or (ROS 20 or 40 mg), Ezetimide, Bempedoic Acid, PCSK9 targeted therapy for at least 4 doses\n* Fasting serum LDL-C ≥70 mg/dL (≥1.80 mmol/L)\n\nExclusion Criteria:\n\n* New York Heart Association class II or IV heart failure or last known left ventricular ejection fraction \\< 30%;\n* Hospitalized for heart failure within 5 years prior to Screening\n* Major adverse cardiac event (MACE) within 3 months prior to Screening;\n* HbA1c ≥10%, or fasting glucose\n* Formal diagnosis of homozygous familial hypercholesterolemia (HoFH)\n* Uncontrolled severe hypertension, defined as either systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥100 mmHg prior to Randomization","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC]","description":"LS mean percent change from baseline to Day 84 in Low-Density Lipoprotein Cholesterol (LDL-C) in the obicetrapib group compared to the placebo group \\[PUC\\]. LDL-C level was measured by preparative ultracentrifugation (PUC).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".25","spread":"2.480"},{"groupId":"OG001","value":"-36.05","spread":"1.769"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline to Day 180 [Martin/Hopkins]","description":"LS mean percent change from baseline to Day 180 in Low-Density Lipoprotein Cholesterol (LDL-C) in the obicetrapib group compared to the placebo group \\[Martin/Hopkins\\]. LDL-C value was calculated using the Martin/Hopkins equation unless TG \\>= 400 mg/dL or LDL-C \\<= 50 mg/dL; where, LDL-C value was measured directly by preparative ultracentrifugation (PUC).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.98","spread":"2.925"},{"groupId":"OG001","value":"-31.80","spread":"2.054"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline to Day 365 [PUC]","description":"LS mean percent change from baseline to Day 365 in Low-Density Lipoprotein Cholesterol (LDL-C) in the obicetrapib group compared to the placebo group \\[PUC\\]. LDL-C level was measured by preparative ultracentrifugation (PUC).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.30","spread":"4.222"},{"groupId":"OG001","value":"-31.14","spread":"2.544"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Apolipoprotein B (ApoB) From Baseline to Day 84","description":"LS mean percent change from baseline to Day 84 in apolipoprotein B (ApoB) in obicetrapib group compared to the placebo group.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.93","spread":"1.758"},{"groupId":"OG001","value":"-21.45","spread":"1.219"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Apolipoprotein B (ApoB) From Baseline to Day 180","description":"LS mean percent change from baseline to Day 180 in apolipoprotein B (ApoB) in obicetrapib group compared to the placebo group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.02","spread":"2.127"},{"groupId":"OG001","value":"-18.30","spread":"1.472"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Apolipoprotein B (ApoB) From Baseline to Day 365","description":"LS mean percent change from baseline to Day 365 in apolipoprotein B (ApoB) in obicetrapib group compared to the placebo group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.15","spread":"2.633"},{"groupId":"OG001","value":"-17.62","spread":"1.663"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Non-HDL-C From Baseline to Day 84","description":"LS mean percent change from baseline to Day 84 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) in obicetrapib group compared to the placebo group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.83","spread":"2.188"},{"groupId":"OG001","value":"-31.62","spread":"1.520"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Non-HDL-C From Baseline to Day 180","description":"LS mean percent change from baseline to Day 180 in Non-high-density Lipoprotein Cholesterol (non-HDL-C) in obicetrapib group compared to the placebo group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.92","spread":"2.658"},{"groupId":"OG001","value":"-27.08","spread":"1.855"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Non-HDL-C From Baseline to Day 365","description":"LS mean percent change from baseline to Day 365 in Non-high-density Lipoprotein Cholesterol (non-HDL-C) in obicetrapib group compared to the placebo group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.64","spread":"3.905"},{"groupId":"OG001","value":"-25.84","spread":"2.305"}]}]}]},{"type":"SECONDARY","title":"Percent Change in HDL-C From Baseline to Day 84","description":"LS mean percent change from baseline to Day 84 in High-density Lipoprotein Cholesterol (HDL-C) in obicetrapib group compared to the placebo group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.26","spread":"5.078"},{"groupId":"OG001","value":"139.92","spread":"3.614"}]}]}]},{"type":"SECONDARY","title":"Percent Change in HDL-C From Baseline to Day 180","description":"LS mean percent change from baseline to Day 180 in High-density Lipoprotein Cholesterol (HDL-C) in obicetrapib group compared to the placebo group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.63","spread":"5.484"},{"groupId":"OG001","value":"133.83","spread":"3.730"}]}]}]},{"type":"SECONDARY","title":"Percent Change in HDL-C From Baseline to Day 365","description":"LS mean percent change from baseline to Day 365 in High-density Lipoprotein Cholesterol (HDL-C) in obicetrapib group compared to the placebo group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.28","spread":"5.994"},{"groupId":"OG001","value":"127.67","spread":"4.222"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Lp(a) From Baseline to Day 84","description":"LS mean percent change from baseline to Day 84 in Lipoprotein (a) \\[Lp(a)\\] in obicetrapib group compared to the placebo group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.52","spread":"9.413"},{"groupId":"OG001","value":"-35.42","spread":"4.527"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Lp(a) From Baseline to Day 365","description":"LS mean percent change from baseline to Day 365 in Lipoprotein (a) \\[Lp(a)\\] in obicetrapib group compared to the placebo group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.37","spread":"37.111"},{"groupId":"OG001","value":"-29.93","spread":"11.224"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Total Cholesterol From Baseline to Day 84","description":"LS mean percent change from baseline to Day 84 in Total Cholesterol (TC) in obicetrapib group compared to the placebo group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.34","spread":"1.796"},{"groupId":"OG001","value":"12.09","spread":"1.268"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Total Cholesterol From Baseline to Day 180","description":"LS mean percent change from baseline to Day 180 in Total Cholesterol in obicetrapib group compared to the placebo group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.44","spread":"2.043"},{"groupId":"OG001","value":"14.43","spread":"1.438"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Total Cholesterol From Baseline to Day 365","description":"LS mean percent change from baseline to Day 365 in Total Cholesterol in obicetrapib group compared to the placebo group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.32","spread":"2.801"},{"groupId":"OG001","value":"13.92","spread":"1.684"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Triglycerides From Baseline to Day 84","description":"LS mean percent change from baseline to Day 84 in Triglycerides in obicetrapib group compared to the placebo group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.16","spread":"4.207"},{"groupId":"OG001","value":"-1.57","spread":"2.580"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Triglycerides From Baseline to Day 180","description":"LS mean percent change from baseline to Day 180 in Triglycerides in obicetrapib group compared to the placebo group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.43","spread":"4.178"},{"groupId":"OG001","value":"4.49","spread":"2.885"}]}]}]},{"type":"SECONDARY","title":"Precent Change in Triglycerides From Baseline to Day 365","description":"LS mean percent change from baseline to Day 365 in Triglycerides in obicetrapib group compared to the placebo group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.39","spread":"5.642"},{"groupId":"OG001","value":"2.27","spread":"3.219"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":118},"commonTop":["Influenza","COVID-19","Hypertension","Nasopharyngitis","Diarrhea"]}}}